Business
Neurochem to Report on Third Quarter of Fiscal 2006
Neurochem to Report on Third Quarter of Fiscal 2006.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n\nNeurochem will host a conference call Thursday, November 9, 2006,\nat 8:30 A.M. ET\n\nLAVAL, QC, Nov. 7 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)\nannounces that it will release its results for the third quarter of fiscal\n2006, ended September 30, tomorrow, after market close.\nThe Company will host a conference call at 8:30 A.M. ET, on Thursday,\nNovember 9, 2006. During the conference call, Dr. Francesco Bellini, Chairman,\nPresident and Chief Executive Officer, Mr. Mariano Rodriguez, Vice President,\nFinance and Chief Financial Officer, and Dr. Denis Garceau, Senior Vice\nPresident, Drug Development will present Neurochem's overall strategy and\nprogress to date, together with the highlights of its financial results.\nTo participate in the conference call, please dial the following numbers\napproximately 10 minutes prior to the start of the call: 416-644-3426 or \n1-866-249-2157. A replay of the conference call will be available for one week\n(until November 16, 2006), commencing one hour after the end of the call. The\ninstant replay numbers are 416-640-1917 or 1-877-289-8525, passcode\n21208556(pound key). Please mention that you are calling for the Neurochem\nconference replay.\n\nAbout Neurochem\n\nNeurochem Inc. is focused on the development and commercialization of\ninnovative therapeutics to address critical unmet medical needs. Eprodisate\n(KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the\ntreatment of AA amyloidosis, and is under regulatory review for marketing\napproval by the U.S. Food and Drug Administration and European Medicines\nAgency. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease,\nis currently in Phase III clinical trials in both North America and Europe and\ntramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused\nby Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.\n\nTo Contact Neurochem\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free number 1-877-680-4500 or\nvisit our Web Site at www.neurochem.com.\n\nCertain statements contained in this news release, other than statements\nof fact that are independently verifiable at the date hereof, may constitute\nforward-looking statements. Such statements, based as they are on the c...